Drug Discontinuation clinical trials

Explore recruiting drug discontinuation clinical trials.

Recruiting drug discontinuation studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Drug Discontinuation trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients Who Have Been Stabilized During Hospitalization for Acute Heart Failure

Poland, Hungary, Czechia

Phase III and phase IV (Integrated) EU CTIS Study details

A Long-term, Open-label Study to Evaluate the Safety and Efficacy of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema

France, Hungary, Italy, Slovakia, Germany, Ireland +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Master rollover study to provide continued access to, and assess, long term safety of the study drugs.

France, Spain, Belgium, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Randomized Evaluation of fleCAinide safety vs. STandard of care in patients with coronary artery disease and Atrial Fibrillation (ReCAST AF).

Belgium

Therapeutic use (Phase IV) EU CTIS Study details

COLchicine and Thiamine in Heart Failure due to Ischemic Heart Disease (COLT-HF)

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

C4391025_AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO LETROZOLE ALONE IN POSTMENOPAUSAL WOMEN 18 YEARS OR OLDER WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER IN THE NEOADJUVANT SETTING

Italy, Spain, France, Slovakia, Germany, Sweden +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Drug Discontinuation trials by city

Drug Discontinuation in Toronto Drug Discontinuation in Vancouver Drug Discontinuation in Montreal Drug Discontinuation in Calgary Drug Discontinuation in Edmonton Drug Discontinuation in Ottawa Drug Discontinuation in Winnipeg Drug Discontinuation in Quebec City Drug Discontinuation in Hamilton Drug Discontinuation in Kitchener Drug Discontinuation in London Drug Discontinuation in Halifax Drug Discontinuation in New York Drug Discontinuation in Los Angeles Drug Discontinuation in Chicago Drug Discontinuation in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease